The phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda (pembrolizumab) in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) met one of its primary endpoints of progression-free survival as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer.
A recent study led by researchers at the University of Arizona Cancer Center and Northern Arizona University found that Native American women were disproportionately affected by vaginal dysbiosis, a disruption in the balance of bacterial that increases the risk of human papillomavirus infection, which can cause cervical cancer.
